"Sangamo's SB-728 is nowhere close to approaching the efficacy of HIV drugs like Gilead Sciences'(GILD_) Stribild or Atripla. I suspect Sangamo executives know SB-728 is unlikely to succeed, but they soldier on because without it, the company's pipeline looks very anemic and can't support the stock's current valuation."
As much as I dislike this guy, he usually has evidence to back up his claims.
Although I have been long this stock, I think that management has overhyped the "HIV cure" thing to grab headlines. Nevertheless, the validity of SGMO's technology is supported by the licensing agreements they have with Shire, Sigma-Aldrich, Dow Agro, etc. It remains an interesting longshot, I think. As someone else has pointed out, AF's blithe assertion that managing HIV is just a matter of popping a pill and living happily ever after is nonsense. Yes, you will probably die of something else, and that something else may be as a result of the medications' side effects. And, on average, you will still die much younger.